Ultramix 300mg (Tren E + Drostanolone + Test E)

DHT-derived injectable — 2alpha-methyl modification at the A-ring confers resistance to 3alpha-HSD, allowing intact muscle-cell activity. Cannot aromatise. Weak AR binding in skeletal tissue but displaces estradiol from SHBG, increasing free-testosterone fraction of any concurrent testosterone — this is the mechanism behind the hardening clinical picture at low body-fat percentages. Effect is visibly null above 15% body fat; below 12%, the lean-tissue definition response becomes dose-responsive. Propionate ester mandates EOD injection schedule; PIP is common and dose-dependent — low-viscosity MCT or GSO carrier oil reduces it materially. Androgenic effects (scalp, prostate) occur but are limited to DHT-sensitive populations.

The 7-carbon heptanoate ester of endogenous testosterone. IM depot kinetics: serum peak at 24–48 h post-injection, steady-state reached after 4–5 half-lives (weeks 3–4). Once-weekly administration produces ~200 ng/dL peak-to-trough variance at 200 mg/week; trough suppression on EOD or twice-weekly splits. Aromatises via CYP19A1 at physiological rates — 0.2–0.3% substrate conversion to estradiol. Target serum E2 on protocol: 25–40 pg/mL (sensitive LC-MS/MS). Aggressive AI dosing that suppresses E2 below 20 pg/mL produces the documented side profile of arthralgia, libido loss, lipid degradation, and cognitive fog — iatrogenic hypoestrogenaemia is a bigger problem than measured hyperoestrogenaemia in most protocols. HPTA shutdown is total within 14 days and predictable; recovery timeline post-cessation is 3–6 months with SERM-based PCT, longer without. Haematocrit drift is the most consistent long-run biomarker — 3–5 percentage points per cycle, additive across cycles without donation.

19-nor 5alpha-reduced analogue of nandrolone. Non-aromatizable — AR-binding affinity roughly 5x testosterone, with measurable agonist activity at the progesterone receptor. The acetate ester generates fast serum peaks and drops; EOD administration is the floor for stable concentrations. Clinical picture: rapid lean-tissue accretion independent of caloric surplus, reduced adipose mass via direct AR signalling in adipocytes, pronounced lipid shift (HDL suppression 40–60%). Prolactin elevation occurs in a subset — cabergoline 0.25 mg twice weekly is the standard response. Renal biomarkers (creatinine, cystatin C) commonly shift upward; this reflects haem metabolite excretion in urine (brick-red pigment) rather than confirmed nephrotoxicity, but CKD-EPI readings should be interpreted with the confounding documented. Nocturnal sympathetic tone (insomnia, diaphoresis) is dose-dependent and resolves on cessation.